Trial reportScientific reports2019
Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay.
Trial report in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review.Clinical reviews in allergy & immunology · 2026Pooled it
- Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.PloS one · 2026Trial
- Interleukin-19 Regulates Adipose Tissue Dysfunction in Obesity: Interplay Between Inflammation and Vascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- From clinical remission to biological stability in psoriasis: an antigen-blood-tissue framework for relapse stratification.Frontiers in immunology · 2026Review
- Validation of CXCL9 as a biomarker of morphoea disease state and severity through longitudinal analysis.The British journal of dermatology · 2025Article
- Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis.Dermatology and therapy · 2025Article
- A Snapshot of Biomarkers in Psoriasis.Current drug discovery technologies · 2025Review
- Comprehensive proteome profiling of molecular endotypes in Japanese adults with moderate-to-severe atopic dermatitis.Frontiers in medicine · 2025Article
- Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.Dermatology and therapy · 2024Article
- The Immunology of Psoriasis-Current Concepts in Pathogenesis.Clinical reviews in allergy & immunology · 2024Review
- Serum Interleukin-19 Levels in Acne Vulgaris Patients of Varying Clinical Severity in Erbil City.Cureus · 2023Article
- Interaction of S100A6 Protein with the Four-Helical Cytokines.Biomolecules · 2023Article
- [Molecular diagnosis of hand eczema].Dermatologie (Heidelberg, Germany) · 2023Review
- Periostin activates distinct modules of inflammation and itching downstream of the type 2 inflammation pathway.Cell reports · 2023Article
- Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseases.Nature communications · 2022Article
- Review
- Combination of FLG mutations and SNPs of IL-17A and IL-19 influence on atopic dermatitis occurrence.Postepy dermatologii i alergologii · 2022Article
- Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients.Healthcare (Basel, Switzerland) · 2021Review
- Skin Barrier Dysregulation in Psoriasis.International journal of molecular sciences · 2021Review
- Topical hypochlorous acid (HOCl) blocks inflammatory gene expression and tumorigenic progression in UV-exposed SKH-1 high risk mouse skin.Redox biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because development of reliable biomarkers in psoriasis and atopic dermatitis has lagged behind therapeutic progress, we created a blood-based test to fill the void in objective methods available for dermatological assessments. Our novel interleukin-19 (IL-19) immunoassay was initially tested to determine concentrations of IL-19 serum levels, then correlated with the psoriasis activity and severity index (PASI) in psoriasis, and the eczema area and severity index (EASI) in atopic dermatitis. Not only was IL-19 increased in psoriasis and correlated to PASI, but ixekizumab administration led to rapid, sustained IL-19 decreases to normal levels, with decreases at 2-weeks correlating with PASI improvement at 16-weeks. IL-19 increased upon ixekizumab withdraw, prior to relapse, and decreased following re-treatment. In baricitinib- and etanercept-treated psoriasis patients, IL-19 decreases also correlated with improvement. Many patients with limited skin disease, including genital psoriasis and psoriatic arthritis patients, also had increased IL-19, which was reduced to normal levels upon ixekizumab treatment, correlating with PASI improvement. We also measured IL-19 in baricitinib-treated atopic dermatitis patients. In atopic dermatitis, IL-19 was significantly elevated, correlated with EASI scores, and decreased with skin improvement. Therefore, measurement of serum IL-19 provides clinicians with an objective disease-activity assessment tool for psoriasis and atopic dermatitis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.